SCHEMBL3452785

SCHEMBL3452785

Fc1ccc(-c2cc(N3CCOCC3)nc(N(Cc3ccccc3)C3=COCO3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.45
NPSR1 Q6W5P4 4/20 0.45
TSHR P16473 3/20 0.45
MAPT P10636 3/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
KMT2A Q03164 1/20 0.43
HTT P42858 3/20 0.40
USP2 O75604 2/20 0.40
GLA P06280 2/20 0.40
CASP1 P29466 2/20 0.40
TP53 P04637 1/20 0.40
NAPEPLD Q6IQ20 6/20 0.40
PIK3CA P42336 3/20 0.39
AKT1 P31749 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MTOR P42345 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449984 0.93 NPSR1 (0.52) HSD17B10NPSR1TSHRMAPTMAPK1
SCHEMBL3452690 0.83 TSHR (0.38) HSD17B10NPSR1TSHRMAPTMAPK1
SCHEMBL3453294 0.81 ESR1 (0.38) HSD17B10NPSR1TSHRMAPTMAPK1
SCHEMBL3451730 0.76 HTT (0.55) HSD17B10NPSR1TSHRMAPTMAPK1
SCHEMBL6001211 0.75 MAPT (0.40) HSD17B10NPSR1MAPTALDH1A1KDM4E
SCHEMBL6001970 0.75 CYP19A1 (0.45) HSD17B10NPSR1MAPTALDH1A1KDM4E
SCHEMBL3232353 0.68 TSHR (0.56) HSD17B10NPSR1TSHRMAPTMAPK1
SCHEMBL6001175 0.67 PDE5A (0.48) HSD17B10NPSR1TSHRMAPTMAPK1
SCHEMBL3450828 0.66 HRH4 (0.42) HSD17B10NPSR1TSHRMAPTMAPK1
SCHEMBL3450643 0.65 HPGD (0.37) HSD17B10NPSR1TSHRMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US claimed
EP-1796673-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-06-20 EP claimed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO claimed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
EP-1796673-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-06-20 EP disclosed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them UMPS, DPYD, TYMS HSD17B10 3514/4885NPSR1 2192/4885TSHR 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.